Abstract
BackgroundData on the adverse effects of newly marketed drugs are limited. The monitoring of adverse drug reactions (ADR) through active pharmacovigilance is vital to patient safety.The new oral anticoagulants dabigatran...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
